Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Cash & Current Investments (2013 - 2026)

Scynexis' (SCYX) quarterly Cash & Current Investments came in at $114.7 million in Q2 2026, up 42.9% on a YoY basis from $80.3 million in Q2 2025, and up 20.74% quarter-over-quarter from $95.0 million in Q1 2026.

Analysis

Scynexis (SCYX) Cash & Current Investments (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Cash & Current Investments for 14 consecutive years, with $114.7 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash & Current Investments rose 42.9% year-over-year to $114.7 million; the trailing twelve-month figure through Jun 2026 stood at $114.7 million (up 42.9% YoY), and the FY2025 full-year result was $40.0 million, down 32.49% from the prior year.
  • Cash & Current Investments rose to $114.7 million in Q2 2026 per SCYX's latest filing, from $95.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $149.2 million in Q3 2023 and bottomed at $40.0 million in Q4 2025.
  • Historically, Cash & Current Investments has averaged $98.3 million across 5 years, with a median of $95.1 million in 2022.
  • The sharpest annual moves came in 2024 and 2025: Cash & Current Investments soared 68.02% in 2024, then sank 51.17% in 2025.
  • Over 5 years, Cash & Current Investments stood at $73.5 million in 2022, then increased by 1.17% to $74.4 million in 2023, then slipped by 20.25% to $59.3 million in 2024, then plunged by 32.49% to $40.0 million in 2025, then jumped by 186.52% to $114.7 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $114.7 million, $95.0 million, and $40.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 13.99 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 3.18 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 7.85 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 7.99 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 5.18 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 5.14 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 3.31 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 1.29 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Scynexis 58.41 Mn -56.29 Mn - 114.70 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 114.70 Mn
Mar 31, 2026 94.99 Mn
Dec 31, 2025 40.03 Mn
Sep 30, 2025 61.03 Mn
Jun 30, 2025 80.27 Mn
Mar 31, 2025 87.47 Mn
Dec 31, 2024 59.30 Mn
Sep 30, 2024 125.00 Mn
Jun 30, 2024 130.74 Mn
Mar 31, 2024 138.96 Mn
Dec 31, 2023 74.36 Mn
Sep 30, 2023 149.20 Mn
Jun 30, 2023 119.54 Mn
Mar 31, 2023 82.71 Mn
Dec 31, 2022 73.50 Mn
Sep 30, 2022 123.57 Mn
Jun 30, 2022 118.70 Mn
Mar 31, 2022 95.21 Mn
Dec 31, 2021 104.48 Mn
Sep 30, 2021 100.11 Mn